Additionally, increased Src activation was observed in a GEP-NET cancer stem cell (CSC) subpopulation and Src inhibition by Dasatinib selectively reduced CSC growth, confirming Src as a relevant therapeutic target in GEP-NET [43]. Here, SRC is linked to cancer.